Autolus Therapeutics plc (AUTL) Revenue by Segment & Business Profile
Product was 100.0% of Autolus Therapeutics plc's revenue across the 2 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AUTLAutolus Therapeutics plcFollow AUTL — free
—
Price chart with a free account
- Market cap
- 409.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
What the company does
Autolus Therapeutics plc is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: Product (100%), License (0%). Trailing twelve-month revenue: $117.4 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Clinical-stage developer
Revenue by geography
fiscal year 2025 · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| United States | 75M | 99.9% | — |
| Europe | 0M | 0.1% | -99.5% |
Autolus Therapeutics plc — questions
- What does Autolus Therapeutics plc do?
- Autolus Therapeutics plc is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: Product (100%), License (0%). Trailing twelve-month revenue: $117.4 million as of 2026-06-30.
- How does Autolus Therapeutics plc make money?
- By the lines it reports in its SEC filings: Product 100.0%, License 0.0% of revenue.
Every figure on this page comes from Autolus Therapeutics plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.